Relatlimab intravenous

DRUG6 trials

Sponsors

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Bristol Myers Squibb International Corporation, Bristol Myers Squibb International Corporation, Institut Bergonie, Bristol Myers Squibb International Corporation, Universitaetsklinikum Essen AöR

Conditions

Adult participants with advanced unresectable or metastatic soft-tissue sarcoma.Adult patients with resectable muscle-invasive urothelial cancer of the bladderAdvanced Malignant TumorsAdvanced/metastatic hepatocellular carcinoma (HCC)Breast cancerII and selected stage III Adefined as stage II and IIIa UCnon-small cell lung cancer (NSCLC) of clinical stages IB

Phase 1

A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

CompletedCTIS2023-508207-21-00

Bristol Myers Squibb International Corporation, Bristol Myers Squibb International CorporationAdvanced Malignant Tumors

Start: 2019-02-08End: 2025-02-14Target: 130Updated: 2025-02-04

A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma (RELATIVITY-106)

CompletedCTIS2024-510649-33-00

Bristol Myers Squibb International CorporationAdvanced/metastatic hepatocellular carcinoma (HCC)

Start: 2022-09-02End: 2025-10-31Target: 53Updated: 2025-10-24

Phase 2

A phase 2 trial in stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab - TURANDORELA

RecruitingCTIS2023-507460-39-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAdult patients with resectable muscle-invasive urothelial cancer of the bladder, defined as stage II and IIIa UC, who have not yet undergone systemic therapy for UBC.

Start: 2024-02-15Target: 90Updated: 2025-05-07

Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung)

CompletedCTIS2024-513074-22-00

Universitaetsklinikum Essen AöRII and selected stage III A, non-small cell lung cancer (NSCLC) of clinical stages IB

Start: 2019-12-02End: 2025-11-27Target: 90Updated: 2025-10-23

CONGRATS : COMBINATION OF NIVOLUMAB PLUS RELATLIMAB IN PATIENTS WITH ADVANCED OR METASTATIC SOFT-TISSUE SARCOMA: A PROOF-OF-CONCEPT RANDOMIZED PHASE II STUDY

Active, not recruitingCTIS2023-509495-42-00

Institut BergonieAdult participants with advanced unresectable or metastatic soft-tissue sarcoma.

Start: 2020-02-27Target: 67Updated: 2025-06-13

Pre-operative phase II trial for breast cancer with nivolumab in combination with novel IO (BELLINI trial)

RecruitingCTIS2024-515080-54-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingBreast cancer

Start: 2019-08-15Target: 120Updated: 2025-07-29